Skip to content
DataLookout
Menu

TXA in TARNCT07828262

The Use of Tranexamic Acid in Decreasing Wound Complication in Total Ankle Replacement.

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Secondary endpoints revised (8)
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of eligible participant enrollment within 12 months
Timeframe: 12 months

Secondary (8)

Percentage of enrolled participants who adhere to the study treatment within the trial.
Percentage of enrolled participants who complete the study's follow-up window
Percentage of consented participants among eligible participants who were approached
Logistical trial implementation barriers that might affect the full trial implementation
Percentage of wound complications assessed by the Foot and Ankle Postoperative Wound Classification scheme from 0 (no complication) to 7 (worse complication).
Show 3 moreShow less
Percentage of re-operations following the initial total ankle arthroplasty
Percentage of participants with Prosthetic Joint Infection assessed by culture swab and treated with antibiotics
Percentage of participants with post-operative Venous Thromboembolism confirmed either via ultrasound or CT

Arms and interventions

TXAExperimental

Patients will receive 1.5g of TXA in 100ml normal saline (NS) solution intravenously within our hour prior to skin incision, and prior to tourniquet inflation. A second dose of 3g in 100ml NS of tranexamic acid will be given topically through a soaked sponge after implant placement and prior to closure. This will be left in place for five minutes.

PlaceboPlacebo comparator

Patients will receive either 100ml normal saline (NS) solution intravenously within our hour prior to skin incision, and prior to tourniquet inflation. Then, a 100ml normal saline solution will be given topically through a soaked sponge after implant placement and prior to closure. This will be left in place for five minutes.

Drugs: Transexamic acid, Normal Saline (0.9% NaCl)

Sites

1 site in 1 country

  • The Ottawa Hospital Civic CampusOttawa, Ontario, Canada